Dataset Information

Innovative measurement of routine physiological variables (heart rate, respiratory rate and oxygen saturation) using a remote photoplethysmography imaging system: a prospective comparative trial protocol.

ABSTRACT:

Introduction

Physiological signals are essential for assessing human health. The absence of a medical device to carry out these measurements remotely is one of the main limitations of telemedicine. Remote photoplethysmography imaging (rPPG) makes it possible to use a camera video to measure some of the most valuable physiological variables: heart rate (HR), respiratory rate (RR) and oxygen saturation (SpO₂). Our objective was to evaluate the value of such remote measurements compared with existing contact point measurements techniques in real-life clinical settings.

Methods and analysis

Prospective hospital-based study that will recruit 1045 patients who require a pulmonary function test. For each patient, measurements of HR, RR and SpO₂, using a standard acquisition system, will be carried out concomitantly with the measurements made by the rPPG system. 30, 60 and 120 s time frames will be used to take measurements. Age, gender and skin phototype will also be collected. The intraclass coefficient correlation will be performed to determine the accuracy and precision of the rPPG algorithm readings.

Ethics and dissemination

The study protocol has been approved by the French Agency for the Safety of Health Products (ANSM registration no. ID RCB 2020-A02428-31) and by a French ethics committee (CPP OUEST I-TOURS-2020T1-30 DM at 30 October 2020). Results will be published in peer-reviewed journals, at scientific conferences and through press releases.

Trial registration number

NCT04660318.

SUBMITTER: Allado E

PROVIDER: S-EPMC8365801 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:This work investigates the estimation biases of remote photoplethysmography (rPPG) methods for pulse rate measurement across diverse demographics. Advances in photoplethysmography (PPG) and rPPG methods have enabled the development of contact and noncontact approaches for continuous monitoring and collection of patient health data. The contagious nature of viruses such as COVID-19 warrants noncontact methods for physiological signal estimation. However, these approaches are subject to estimation biases due to variations in environmental conditions and subject demographics. The performance of contact-based wearable sensors has been evaluated, using off-the-shelf devices across demographics. However, the measurement uncertainty of rPPG methods that estimate pulse rate has not been sufficiently tested across diverse demographic populations or environments. Quantifying the efficacy of rPPG methods in real-world conditions is critical in determining their potential viability as health monitoring solutions. Currently, publicly available face datasets accompanied by physiological measurements are typically captured in controlled laboratory settings, lacking diversity in subject skin tones, age, and cultural artifacts (e.g, bindi worn by Indian women). In this study, we collect pulse rate and facial video data from human subjects in India and Sierra Leone, in order to quantify the uncertainty in noncontact pulse rate estimation methods. The video data are used to estimate pulse rate using state-of-the-art rPPG camera-based methods, and compared against ground truth measurements captured using an FDA-approved contact-based pulse rate measurement device. Our study reveals that rPPG methods exhibit similar biases when compared with a contact-based device across demographic groups and environmental conditions. The mean difference between pulse rates measured by rPPG methods and the ground truth is found to be ~2% (1 beats per minute (b.p.m.)), signifying agreement of rPPG methods with the ground truth. We also find that rPPG methods show pulse rate variability of ~15% (11 b.p.m.), as compared to the ground truth. We investigate factors impacting rPPG methods and discuss solutions aimed at mitigating variance.

Project description:BackgroundMonitoring systems have been developed during the COVID-19 pandemic enabling clinicians to remotely monitor physiological measures including pulse oxygen saturation (SpO2), heart rate (HR), and breathlessness in patients after discharge from hospital. These data may be leveraged to understand how symptoms vary over time in COVID-19 patients. There is also potential to use remote monitoring systems to predict clinical deterioration allowing early identification of patients in need of intervention.MethodsA remote monitoring system was used to monitor 209 patients diagnosed with COVID-19 in the period following hospital discharge. This system consisted of a patient-facing app paired with a Bluetooth-enabled pulse oximeter (measuring SpO2 and HR) linked to a secure portal where data were available for clinical review. Breathlessness score was entered manually to the app. Clinical teams were alerted automatically when SpO2 < 94 %. In this study, data recorded during the initial ten days of monitoring were retrospectively examined, and a random forest model was developed to predict SpO2 < 94 % on a given day using SpO2 and HR data from the two previous days and day of discharge.ResultsOver the 10-day monitoring period, mean SpO2 and HR increased significantly, while breathlessness decreased. The coefficient of variation in SpO2, HR and breathlessness also decreased over the monitoring period. The model predicted SpO2 alerts (SpO2 < 94 %) with a mean cross-validated. sensitivity of 66 ± 18.57 %, specificity of 88.31 ± 10.97 % and area under the receiver operating characteristic of 0.80 ± 0.11. Patient age and sex were not significantly associated with the occurrence of asymptomatic SpO2 alerts.ConclusionResults indicate that SpO2 alerts (SpO2 < 94 %) on a given day can be predicted using SpO2 and heart rate data captured on the two preceding days via remote monitoring. The methods presented may help early identification of patients with COVID-19 at risk of clinical deterioration using remote monitoring.